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Summary
Signal transduction pathways, which regulate cell growth and survival, are up-regulated in many cancers and there is consider-
able interest in their pharmaceutical modulation for cancer treatment. However inhibitors of single pathway components induce
feedback mechanisms that overcome the growth moderating effect of the inhibitor. Combination treatments have been proposed
to provide a more complete pathway inhibition. Here the effect of dual treatment of cancer cells with a pan-Akt and a pan-mTOR
inhibitor was explored. Breast (SKBr3 and MDA-MB-468) and colorectal (HCT8) cancer cells were treated with the pan-Akt
inhibitor MK2206 and pan-mTOR inhibitor AZD8055. Cytotoxic effect of the two drugs were determined using the MTT assay
and the Combination Index and isobolomic analysis used to determine the nature of the interaction of the two drugs. Flow
cytometry and western blot were employed to demonstrate drug effects on cell cycle distribution and phosph-Aktser473 expres-
sion. Radiolabelled ([methyl-3H]) Choline uptake was measured in control and drug-treated cells to determine the modulatory
effects of the drugs on choline incorporation. The two drugs acted synergistically to inhibit the growth rate of each cancer cell
line. Flow cytometry demonstrated G0/G1 blockade with MK2206 and AZD8055 which was greater when cells were treated
with both drugs. The incorporation of [methyl-3H] choline was found be decreased to a greater extent in cells treated with both
drugs compared with cells treated with either drug alone.Conclusions Pan-mTOR and pan-Akt inhibitionmay be highly effective
in cancer treatment and measuring changes in choline uptake could be useful in detecting efficacious drug combinations.
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Introduction
Cancer growth and development are frequently associated
with upregulation of intracellular signalling pathways, includ-
ing the PI3K/Akt/mTOR pathway, which drives cellular pro-
liferation resulting in the uncontrolled cell growth that defines
cancer [1]. The increased levels of activation of PI3K/Akt/
mTOR can be the result [2] of activating mutations of genes
coding for PI3K or Akt (also known as PKB (protein kinase
B)), kinases that stimulate the pathway, or inactivating
mutations in the gene for the inhibitory phosphatase, PTEN
(phosphatase and tensin homolog).
In view of the central role of PI3K/Akt/mTOR in cancer
cell proliferation in many tumour types there is much inter-
est in oncology in the use of inhibitors targeting compo-
nents of this pathway [3]. Although the use of such inhib-
itors has been shown to decrease cancer cell proliferation
and survival, their efficacy as single-agents is poor [4] due
to activation of feedback mechanisms [5, 6] so attenuating
the clinical benefit from the drug. Consequently their use in
combination treatments has been recommended [7] and it
has been shown that drug combinations, including the dual
use of Akt and mTOR inhibitors, are more efficacious than
single drug regimens as they bring about a more complete
pathway inhibition [8]. However drugs targeting the PI3K/
Akt/mTOR pathway are associated with unpleasant and
potentially dangerous side effects including nausea, diar-
rhoea and hyperglycaemia [9] which may be enhanced in
drug combinations [8].
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Therefore, early detection of the clinical benefit of multi-drug
regimens is an important aspect of their utilisation. Positron emis-
sion tomography (PET) is ahighly sensitivemedical imaging tech-
nique that facilitates non-invasive measurement of metabolism.
The most commonly used PET tracer is FDG (2-[18F] Fluor-2-
deoxy-D-glucose)andmanystudieshavedemonstratedthatchang-
es in its tumour incorporation accompanies treatment response.
However this is not always the case for drugs targeting the PI3K/
Akt/mTOR pathway [10]. Choline uptake has been shown to be
associated with proliferation rate [11] and [11C] choline-PET has
beenappliedtoresponsedetectiontotreatmentsthattargetreceptors
upstreamof signalling pathways [12].Herewehave demonstrated
that treatment of breast cancer and colorectal cancer cells with a
pan-mTOR inhibitor synergistically increases the growth-
inhibitoryactionoftheAkt-inhibitorMK2206whichcorresponded
with changes in the incorporation of radiolabelled choline.
Materials and methods
Materials
Breast cancer cells (MDA-MB 468 and SKBr3) and colon can-
cer cells (HCT8, HCT116 and SW620) were purchased from
American Type Cell Culture Collection (ATCC). Unless stated
otherwise all chemicals were purchased from Sigma-Aldrich
chemical company. The inhibitors used in this study, MK2206
and AZD8055 targeting Akt and mTORC1 and 2 respectively,
were obtained from Cambridge Biosciences (Cambridge, UK).
Cell culture and cytotoxicity assay
Cells were grown in Dulbecco’s Modified Eagle medium sup-
plemented with 10% foetal bovine serum containing penicillin
(100 units/ml) / streptomycin (10 μg/ml) in 75cm2 tissue culture
flasks and incubated at 37 °C in a CO2 incubator (Thermo-
Scientific UK) with a humidified atmosphere of 95% air; 5%
CO2. When they reached confluency cells were detached with
trypsin and after addition of medium the cells were counted in a
haemocytometer (Improved Neubauer, Weber Scientific
International UK) and cell suspensions of 30 × 103 cells/ ml pre-
pared. Cell suspension (100 μl) was added to rows 2–10 (col-
umns B to G) and 100ul of medium added to row H
(background) of 96 well plate. The plates were then incubated
at 37 °C for 24 h to allow cells to adhere. Medium (100 μl) was
added to row B and H. To the remaining cells were added either
MK2206 (0.04-20 μM) or AZD8055 (8-1000 nM) in increasing
concentrations to rows C to G and the plate incubated for a
further 72 h. The cytotoxic effect of each drug was assessed by
theMTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium
bromide) assay. Briefly medium was removed from the wells
then replaced with medium containing 0.5 mg MTT/ml and the
plates incubated in the incubator at 37 °C for 1-2 h depending on
the time taken for the cells to appear dark purple. The medium
was then removed and the purple aqueous-insoluble crystals that
formed in the cells by reduction of MTT were solubilised by
addition of 100 μl of DMSO. After a brief (10s) agitation the
absorbance was measured in a multiwell platereader with the
absorbance filter at 540 nm. The IC50 values of each drug were
calculated using CompuSyn software (ComboSyn, Paramus, NJ)
from the absorbance of drug-treated cells expressed as a percent-
age of absorbance of control (untreated) in well 2.
To determine the effect of combining MK2206 and
AZD8055 on proliferation, cells were set up as for the dose
curves but before adding the range of drug doses, cells were
treated with a dose of the other drug that was known to appre-
ciably (30–40%) decrease cell proliferation. The dose curves
with and without combined treatment were then used to cal-
culate the combination index as described by Chou and
Talalay (Chou 2010) [13] using the following formula:
CI ¼ Xa=Xbþ Ya=Yb:
Suitable drug concentrations (Xa, Ya) are used such that
their combined effect reduces cell viability to about 20–60%
that of the control. Xb and Yb are the concentrations of each
drug which when used alone produce the same level of growth
inhibition as the combination. The data obtained from the dose
curves in the presence and absence of the second drug were
also subject to Isobolomic analysis.
Western blot analysis of Akt, p-Akt (Ser473), mTOR
and p-mTOR (Ser2481) protein expression
MDA-MB 468 cells were treated with theMK2206, AZD8055
or the two drugs combined for 24 h and then washed with 5 ml
ice cold PBSwash before harvesting by scrapingwith 150μl of
lysis buffer (PBS containing 1 mM DTT, a protease inhibitor
cocktail, 10 mM sodium pyrophosphate and 1 mM sodium
orthovanadate). Samples were kept frozen until they were lysed
with a probe sonicator for 30 s. Protein concentration was de-
termined using the bicinchonininic acid (BCA) assay. Lysates
(25 μg protein/well) were resolved on 4%–12% acrylamide
bis–tris gels (Invitrogen) and the proteins transferred to
Immobilon-P polyvinylidene difluoride membranes
(Millipore) at 30 V for 1.5 h using a wet transfer system
(Invitrogen). Membranes were blocked for 1 h at room temper-
ature in sea block PBS for the Akt antibody and 1% (w/v) BSA
for the p-Akt antibody. Membranes were blotted with antibod-
ies in PBST (PBS containing 0.1% Tween 20) at 4 °C over-
night. Akt and p-Akt (1/667 dilution) and mTOR and p-mTOR
(1/1000 dilution) were used. Membranes were washed four
times in PBST prior to 1 h incubation with the appropriate
anti-rabbit fluorescent secondary antibody in PBST in the dark.
The secondary antibody used was IRdye680 donkey anti-rabbit
secondary antibody (Licor) (1/10000 dilution). Blots were
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drained and wrapped in cling film to prevent drying and im-
aged using the Odyssey® CLx LI-CORE imaging system.
Images were then analysed using the Odyssey Image Studio
Lite (LI-CORE) software.
Flow cytometry analysis of cell cycle distribution
Cells were seeded in 25cm2 flasks with 2 ml medium (1 × 106
cells) and incubated at 37 °C until treated with IC50 concentra-
tions of each inhibitor or in combinations for 24 h, then
trypsinized. After two PBS washes they were re-suspended in
300 μl PBS followed by fixation with 70% ice-cold ethanol
during mixing on a vortex. The fixed cells were kept at −20 °C
prior to flow cytometry analysis. For cell cycle analysis, fixed
cells were adjusted to 5 × 105 cells/ml and washed 2 times with
PBS supplemented with 1% bovine serum albumin (BSA). Then
the cells were centrifuged at 1000 g for 5mins and suspended in
1 ml of staining buffer containing 50μg/ml propidium iodide,
50μg/ml ribonuclease A and 0.1% v/v triton-x-100 in PBS and
incubated for 15 min at room temperature. The stained nuclei
were kept at 4 °C and protected from light. Flow cytometry was
performed using 488 nm laser light on a FACSCalibur flow
cytometer (Becton Dickinson, UK) and CELLQuest software
(Becton Dickinson, UK) equipped for fluorescence detection,
forward, 90° angle light scatter and doublet discrimination. The
data analysis was carried out with Flow-jo cell cycling software.
[Methyl-3H]-choline incorporation
For each experiment 12 flasks (25cm2) were seeded with 1 × 106
cells in 2 ml of medium and allowed to attach overnight at 37oC.
Cells were then treated by addition of medium (6 flasks) or
medium containingAZD8055 (6 flasks) and incubated overnight
at 37 °C. To 3 untreated and 3 AZD8055-treated flasks of cells
was addedMK2206 and the flasks incubated for a further 24 h at
37 °C. Cells were then incubated with fresh medium containing
[methyl-3H]-choline (37 kBq/ml) for 15mins [14]. Then the cells
were washed 5 times with phosphate buffer saline (PBS) and
detached by treatment with trypsin (0.35 ml). After addition of
medium (0.35 ml) to neutralise the trypsin half the cell suspen-
sion was added into 5 ml of Ultima Gold scintillation fluid
(Perkin-Elmer UK) in a scintillation vial (Perkin-Elmer UK)
and counted in the liquid scintillation counter (Packard
Tricarb2300) for 10 mins per vial. The remaining cells were
centrifuged andwashedwith 1ml of PBS and the pellet dissolved
in 0.1 ml of NaOH (1 M) overnight for determination of protein
concentration after neutralization with 0.1 ml of HCl (1 M).
Protein assay
Protein assay was done by using the BCA protein assay kit
(Sigma-Aldrich UK) with Bovine serum albumin (BSA) as a
standard according to manufacturer’s protocol.
Statistical analysis
Statistical differences between means were determined using
the data acquired from at least 3 independent experiments.
Significance was set at p < 0.05. Statistical analysis for finding
IC50 was performed using CompuSyn software (ComboSyn,
Paramus, NJ). Combination index (CI) were calculated from
fractions of dose-effect curves by Chou and Talalay [13] for
drug interactions.
Results
Up-regulation of PI3K/Akt/mTOR is an important indicator
for treatment with inhibitors of this pathway therefore an ini-
tial screen of phospho-Aktser473 and phosphor-mTORser2481
expression was carried out in 2 breast and 3 colorectal cancer
cell lines. The western blots are shown in Fig. 1. SKBr3,
MDA-MB-468 and HCT8 cells expressed p-Aktser473 at high
levels. All lines expressed similar levels of p-mTORser2481
protein.
Figure 2 shows the effect of the pan-Akt inhibitor MK2206
and the pan-mTOR inhibitor AZD8055 on the growth rate of
the breast cancer cell lines MDA-MB-468 and SKBr3 and the
colorectal cell line HCT8. The IC50 doses of each drug are
shown in Table 1. The effect of combining AZD8055 with a
clinically relevant dose of MK2206 [3] that decreases cell
growth by 30–40% (310 nM) is shown in Fig. 3. The com-
bined effect of these drugs were then assessed using the
Total mTOR
pmTORser2481
Total Akt
pAktser473
β-actin
1       2      3     4      5      
Fig. 1 Expression of total mTOR, p-mTORser2481, total Akt and
pAktser473 in SKBr3 (Lane 1), MDA-MB-468 (Lane 2), HCT8 (Lane
3), HCT116 (Lane 4) and SW620 (Lane 5)
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combination index Table 2) and found to be synergistic. The
results were confirmed using isobolomics using CompuSyn
and the isobolograms displayed in Fig. 4.
To confirm that MK2206 and AZD8055 down-regulated
pAktser473 [15, 16] the expression of p-Aktser473 and total Akt
by MDA-MB-468 cells untreated and treated with MK2206
(310 nm), AZD8055 (31, 62 and 125 nM) or both drugs com-
bined was determined. The results shown in Fig. 5 demon-
strate that both drugs decrease the level of pAktser473 and that
combining MK with AZD resulted in greater decreases in
pAktser473 levels.
The effects of MK2206 and AZD8055 alone or in combi-
nation on cell cycle distribution was determined in SKBr3 and
MDA-MB-468 cells and the results shown in Fig. 6. Each drug
alone significantly (P < 0.05) increased the proportion of cells
in G0/G1 and decreased the proportion in G2 in both cells lines.
The two drugs together significantly (P < 0.05) increased the
proportion of cells in G0/G1 and decreased the proportion of
cells in G2 compared with either drug alone in both cell lines.
Treatment of SKBr3, MDA-MB-468 and HCT8 cells
with AZD8055 and MK2206 significantly (p < 0.05) de-
creased choline incorporation compared with treatment
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Fig. 3 Inhibition of proliferation of SKBr3 (a), MDA-MB-468 (b) and
HCT8 (c) cancer cells by treatment with increasing concentrations
AZD8055 alone (filled circles) and in the presence of an IC40 dose
MK2206 (open circles) determined using the MTT assay. Results
expressed as absorbance at 540 nm relative to cells in untreated wells (%)
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Fig. 2 Inhibition of proliferation of SKBr3 (empty squares), MDA-MB-
468 (filled circles) and HCT8 (filled squares) cancer cells by treatment
with increasing concentrations MK2206 (a) and AKD8055 (b) deter-
mined using the MTT assay. Results expressed as absorbance at 540 nm
relative to cells in untreated wells (%)
Table 1 IC50 doses ofMK2206 andAKD8055 for breast and colorectal
cancer cells treated for 72 h
Cell lines Signalling inhibitors IC50
MDA-MB468 MK2206 2.16 ± 0.206 μM
AZD 8055 65.1 ± 11 nM
HCT8 MK2206 1.58 ± 0.66 μM
AZD8055 181.77 ± 46.05 nM
SKBr3 MK2206 0.479 ± 0.15 μM
AZD8055 19.407 ± 5.39 nM
Table 2 Combination indices for breast and colorectal cancer cells
treated with MK2206 and AZD8055
Cell lines Combination Index (CI)
SKBr3 0.334 ± 0.23
HCT8 0.31 ± 0.03
MDA-MB468 0.456 ± 0.27
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with either MK2206 or AZD8055 alone (results shown
in Fig. 7).
Discussion
Inhibition of intracellular signalling pathways is an attractive
strategy for anticancer treatment. However due to feedback
mechanisms and cross-talk cancer cells are able to minimise
a
b
c
Synergism 
Antagonism
Fig. 4 Normalised isobolograms (produced using CompuSyn software
(ComboSyn, Paramus, NJ)) for the combination of MK2206 (x-axis) and
AZD8055 (y-axis) treatment of SKBr3 (a), MDA-MB-468 (b) and HCT8
(c) cells
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Fig. 5 Expression of total and pAktser473 by MDA-MB-468 cells treated
with MK2206, AZD8055 and both combined for 24 h
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Fig. 6 Effect of treatment of SKBr3 (a) and MDA-MB-468 (b) cells for
24 h with MK2206 (white), AKD8055 (squares) and both combined (diag-
onal lines) (untreated Black) on cell cycle distribution using flow cytometry
analysis (* indicates significant difference (p < 0.05) from control)
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the proliferation-attenuating effects of signal pathway
inhibiting drugs when administered as single agents. The
PI3K/Akt/mTOR pathway is up-regulated in cancer due to sev-
eral mechanism including activating mutations of PI3K and
Akt, inactivating mutations of PTEN and over-expression of
upstream receptors such as the tyrosine kinase human epithelial
receptor family (HER). An initial screen of several cell lines
confirmed high phospho-Aktser473 expression in SKBr3,
MDA-MB-468 and to a lesser extent in HCT8 cells.
SKBr3 cells over-express HER-2 [10, 17] but are wild type
for PI3K and PTEN, MDA-MB-468 cells harbour mutant
PTEN [17] and HCT8 are mutant for PIK3CA [18].
MK2206 and AZD8055 synergistically inhibited proliferation
of SKBr3, MDA-MB-468 and HCT8 cells. This would sug-
gest that the underlying mechanism of PI3K/Akt/mTOR up-
regulation is not necessarily a factor in the synergistic growth
inhibitory effect of pan-Akt and pan-mTOR inhibitors.
Treatment of cancer cells with AZD8055 [19, 20] and
MK2206 [21, 22] has been shown to cause accumulation of
cells in G0/G1. Thus English et al. [19] found that response to
treatment of uterine serous carcinoma cell lines, especially cells
over-expressing HER2, with 1 μM or 5 μM AZD8055 was
associated with G0/G1 cell cycle arrest in a concentration-
dependent manner. Qian et al. 2016 [20] has reported that the
pan-mTOR kinase inhibitors MTI-31 and AZD8055 induce
G0/G1 cell cycle arrest corresponding with suppression of cy-
clin D1 and c-Myc in HER2+/PIK3CA mutant breast cancer
cells. Similarly for the pan-Akt inhibitor, MK2206, studies [21,
22] have demonstrated that treatment with this drug induced
G0/G1-phase arrest which was associated with a marked de-
crease in cyclin D1 levels in hepatocellular carcinoma HepG2
cells. In agreement with these studies we have found MK2206
and AZD8055 induced G0/G1 cell cycle arrest in breast cancer
and colorectal cancer lines whilst the combination of MK2206
with AZD8055 exacerbated G0/G1 cell cycle arrest.
Progression of human mammary epithelial cells to a malig-
nant phenotype is associated with altered membrane choline
metabolism [23] due to changes in the expression of enzymes
that control anabolic and catabolic reactions of choline metab-
olism resulting in increased levels of choline-containing pre-
cursors and breakdown products of membrane phospholipids
[24]. Increased phosphocholine levels are frequently found in
cancer tissue [25, 26] and studies have shown that the uptake
and phosphorylation of radiolabelled choline by cancer cells
correlates with proliferation rate [11]. Here choline uptakewas
decreased by breast cancer and colorectal cancer cells when
treated with both MK2206 and AZD8055 but MK2206 alone
only decreased choline uptake significantly in the breast can-
cer cell lines. Studies using 31P-NMR spectroscopy have dem-
onstrated that inhibition of PI3K/AKT/mTOR signalling path-
way by PI-103 reduced choline kinase activity, resulting in
decreased in PCho in colon cancer cells [27]. Venkatesh et
al. [28] has also demonstrated that treatment with the PI3K
inhibitor LY294002 and mTOR inhibitor everolimus de-
creased phosphocholine levels associated with decreased in
choline kinase activity in glioblastoma cell lines. However
other studies have shown that phosphocholine content of can-
cer cells isn’t consistently altered by treatment with PI3K/Akt/
mTOR inhibitors [29].
In summary treatment of tumour cells with pan-Akt and
pan-mTOR synergistically inhibited the growth of cancer cells
and was associated with arrest in G0/G1. Radiolabelled cho-
line uptake was most strongly decreased by dual drug treat-
ment and in combination with PET may be a useful non-
invasive indicator of efficacious drug combinations.
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